



Financial Tear Sheet

Corporate Profile

Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company's approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.

Primary IR Contact

Kristin Hodous

Blueprint Medicines

Phone: 617-714-6674

E-mail:

khodous@blueprintmedicines.com


Stock Information

BPMC (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$78.33
Change (%)	0.00 (0.00%)
Volume	0
52 Week Low	\$34.38
Market Cap	\$3,423,336,748
Rolling EPS	-3.89
PE Ratio	0

Shares Outstanding 43,704,031

Data as of April 25, 2018 4:00 p.m. ET



Recent Press Releases & Upcoming Events

April 25, 2018

[Blueprint Medicines to Report First Quarter 2018 Financial Results on Wednesday, May 2, 2018](#)

Date	Title
May 02, 2018 8:30 a.m. ET	Q1 2018 Blueprint Medicines Corp Earnings Conference Call

April 15, 2018

[Blueprint Medicines Publication in Cancer Discovery Highlights Preclinical and Clinical Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667](#)

April 15, 2018

[Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors](#)

SEC Filings

Filing Date	Form
April 16, 2018	8-K
March 21, 2018	4

Corporate Governance

Jeffrey Albers	Chief Executive Officer
--------------------------------	-------------------------

March 20, 2018	4	Marion. Dorsch, Ph.D	Chief Scientific Officer
March 19, 2018	4	Anthony Boral, M.D-Ph.D.	Chief Medical Officer
		Kate Haviland	Chief Business Officer
		Christoph Lengauer, Ph.D.	Executive Vice President

Data provided by Nasdaq. Minimum 15 minutes delayed.